GLP-1 Receptor Agonist Mechanisms and Clinical Implications

Core Pancreatic Mechanisms

The American College of Cardiology recommends GLP-1 receptor agonists for their glucose-dependent insulin secretion mechanism, which explains the low hypoglycemia risk, with both first- and second-phase insulin secretion enhanced, approaching those of healthy subjects 1, 2
GLP-1 receptor activation inhibits glucagon secretion from pancreatic alpha cells in a glucose-dependent manner, reducing hepatic glucose production, with a potential preservation of pancreatic beta cell mass 1, 2

GLP-1 delays gastric emptying by inhibiting gastric peristalsis while increasing pyloric tone, mediated through vagal nerve pathways, resulting in reduced phasic gastric contractions, delayed gastric emptying, reduced gastric acid secretion, and increased fasting and postprandial gastric volumes 1, 3
Short-acting GLP-1 receptor agonists maintain more pronounced effects on gastric emptying than long-acting formulations due to tachyphylaxis, with acute and intermittent infusions having more pronounced effects than continuous infusions 2, 3, 4

GLP-1 receptors in the hypothalamus and brainstem nuclei mediate appetite, satiety, energy intake, and expenditure, with systemic GLP-1 receptor agonists suppressing the arcuate nucleus and inducing meal termination in parabrachial neurons 1, 4
Receptors in the hepatoportal region and on afferent vagal nerve endings in the intestinal mucosa generate central nervous system signals that influence metabolism, with GLP-1 receptors also found in the hippocampus, neocortex, spinal cord, and cerebellum 1, 4

GLP-1 receptors are localized primarily to the sinoatrial node of the heart, with cardioprotective mechanisms including improved myocardial substrate utilization, anti-inflammatory and anti-atherosclerotic effects, reduced myocardial ischemia injury, and lower systemic and pulmonary vascular resistance 1, 4

GLP-1 receptor agonists result in substantially greater weight loss in non-diabetic patients, with weekly semaglutide 2.4 mg reducing mean body weight by 14.9% in non-diabetic, overweight/obese patients 4
The American Heart Association recommends avoiding GLP-1 receptor agonists in patients with pre-existing gastroparesis or delayed gastric emptying, as they may exacerbate symptoms, and starting at low doses and titrating slowly to minimize gastrointestinal side effects 1, 3, 4

The American College of Cardiology recommends Liraglutide as it has been shown to reduce 3-point MACE (cardiovascular death, nonfatal MI, or nonfatal stroke) by 13% and all-cause mortality by 15% in patients with type 2 diabetes and established cardiovascular disease 5
Semaglutide reduced 3-point MACE by 26% in a moderately sized trial, though this was designed as a noninferiority study rather than powered for superiority 5